Research Article
Nomogram Models Based on the Gene Expression in Prediction of Breast Cancer Bone Metastasis
Table 3
Cox regression analysis of the GESBN models and clinical variables in the validation cohorts.
| Overall survival | Variables | Univariate analysis | Multivariate analysis | HR (95% CI) | value | HR (95% CI) | value |
| N stage | 0.856 (0.388–1.887) | 0.700 | 0.761 (0.343–1.687) | 0.501 | Grade | 1.210 (0.364–4.019) | 0.756 | 1.198 (0.337–4.265) | 0.780 | T stage | 1.696 (0.980–2.930) | 0.059 | 1.407 (0.827–2.393) | 0.208 | Risk score | 2.719 (1.300–5.686) | 0.008 | 2.442 (1.130–5.227) | 0.023 |
| Progression-free survival | Grade | 1.635 (0.792–3.374) | 0.184 | 1.323 (0.535–3.272) | 0.545 | Age | 1.022 (0.987–1.058) | 0.227 | 1.037 (0.996–1.080) | 0.074 | PR status | 0.333 (0.133–0.835) | 0.019 | 0.572 (0.194–1.686) | 0.311 | Risk score | 2.714 (1.582–4.655) | <0.001 | 2.773 (1.469–5.235) | 0.002 |
|
|
abrAbbreviations. GESBN, gene expression signature-based nomogram; HR, hazard ratio; 95% CI, 95% confidence interval; PR status, progesterone receptor status.
|